Prestige Consumer Healthcare (PBH) 10-Q 8 Feb 24 2024 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Dec. 31, 2023	Feb. 02, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-32433
Entity Registrant Name	PRESTIGE CONSUMER HEALTHCARE INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-1297589
Entity Address, Address Line One	660 White Plains Road
Entity Address, City or Town	Tarrytown
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10591
City Area Code	914
Local Phone Number	524-6800
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	PBH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		49,649,288
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Revenues
Total revenues	$ 282,741	$ 275,524	$ 848,366	$ 841,856
Cost of Sales
Cost of sales excluding depreciation	122,794	123,251	369,772	364,631
Cost of sales depreciation	2,009	1,871	5,963	5,695
Cost of sales	124,803	125,122	375,735	370,326
Gross profit	157,938	150,402	472,631	471,530
Operating Expenses
Advertising and marketing	39,466	30,423	115,799	114,193
General and administrative	26,003	26,536	79,687	79,688
Depreciation and amortization	5,637	6,259	16,869	19,067
Total operating expenses	71,106	63,218	212,355	212,948
Operating income	86,832	87,184	260,276	258,582
Other expense
Interest expense, net	16,575	17,917	51,900	50,188
Other expense (income), net	682	1,150	(327)	2,787
Total other expense, net	17,257	19,067	51,573	52,975
Income before income taxes	69,575	68,117	208,703	205,607
Provision for income taxes	16,529	16,166	48,822	47,361
Net income	$ 53,046	$ 51,951	$ 159,881	$ 158,246
Earnings per share:
Basic (in USD per share)	$ 1.07	$ 1.05	$ 3.21	$ 3.17
Diluted (in USD per share)	$ 1.06	$ 1.04	$ 3.19	$ 3.14
Weighted average shares outstanding:
Basic (in shares)	49,740	49,693	49,731	49,919
Diluted (in shares)	50,125	50,186	50,134	50,392
Comprehensive income, net of tax:
Currency translation adjustments	$ 7,465	$ 6,970	$ 3,035	$ (9,667)
Net loss on termination of pension plan	0	0	0	(790)
Total other comprehensive income (loss)	7,465	6,970	3,035	(10,457)
Comprehensive income	60,511	58,921	162,916	147,789
Net sales
Revenues
Total revenues	282,715	275,495	848,321	841,783
Other revenues
Revenues
Total revenues	$ 26	$ 29	$ 45	$ 73

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Current assets
Cash and cash equivalents	$ 63,615	$ 58,489
Accounts receivable, net of allowance of $18,710 and $20,205, respectively	174,288	167,016
Inventories	148,637	162,121
Prepaid expenses and other current assets	7,246	4,117
Total current assets	393,786	391,743
Property, plant and equipment, net	70,356	70,412
Operating lease right-of-use assets	10,695	14,923
Finance lease right-of-use assets, net	2,206	4,200
Goodwill	527,878	527,553
Intangible assets, net	2,328,529	2,341,893
Other long-term assets	6,303	3,005
Total Assets	3,339,753	3,353,729
Current liabilities
Accounts payable	39,339	62,743
Accrued interest payable	15,197	15,688
Operating lease liabilities, current portion	5,650	6,926
Finance lease liabilities, current portion	2,188	2,834
Other accrued liabilities	65,063	72,524
Total current liabilities	127,437	160,715
Long-term debt, net	1,199,340	1,345,788
Deferred income tax liabilities	397,147	380,434
Long-term operating lease liabilities, net of current portion	6,138	9,876
Long-term finance lease liabilities, net of current portion	195	1,667
Other long-term liabilities	8,919	8,165
Total Liabilities	1,739,176	1,906,645
Commitments and Contingencies — Note 14
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 55,291 shares at September 30, 2023 and 54,857 shares at March 31, 2023	553	548
Additional paid-in capital	556,452	535,356
Treasury stock, at cost - 5,680 shares at December 31, 2023 and 5,165 shares at March 31, 2023	(219,638)	(189,114)
Accumulated other comprehensive loss, net of tax	(28,529)	(31,564)
Retained earnings	1,291,739	1,131,858
Total Stockholders' Equity	1,600,577	1,447,084
Total Liabilities and Stockholders' Equity	$ 3,339,753	$ 3,353,729

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable, current	$ 18,710	$ 20,205
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	55,329,000	54,857,000
Treasury stock (in shares)	5,680,000	5,165,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive Income (Loss)	Retained Earnings
Common stock, beginning balance (in shares) at Mar. 31, 2022		54,430,000
Equity, beginning balance at Mar. 31, 2022	$ 1,577,611	$ 544	$ 515,583	$ (133,648)	$ (19,032)	$ 1,214,164
Treasury stock, beginning balance (in shares) at Mar. 31, 2022				4,151,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 9,756		9,756
Exercise of stock options (in shares)	200,200	200,000
Exercise of stock options	$ 7,173	$ 2	7,171
Issuance of shares related to restricted stock (in shares)		222,000
Issuance of shares related to restricted stock	0	$ 2	(2)
Treasury share repurchases (in shares)				1,014,000
Treasury share repurchases	(55,466)			$ (55,466)
Net income	158,246					158,246
Comprehensive income	(10,457)				(10,457)
Common stock, ending balance (in shares) at Dec. 31, 2022		54,852,000
Equity, ending balance at Dec. 31, 2022	1,686,863	$ 548	532,508	$ (189,114)	(29,489)	1,372,410
Treasury stock, ending balance (in shares) at Dec. 31, 2022				5,165,000
Common stock, beginning balance (in shares) at Sep. 30, 2022		54,690,000
Equity, beginning balance at Sep. 30, 2022	1,619,841	$ 547	524,392	$ (189,098)	(36,459)	1,320,459
Treasury stock, beginning balance (in shares) at Sep. 30, 2022				5,164,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,433		2,433
Exercise of stock options (in shares)		161,000
Exercise of stock options	5,684	$ 1	5,683
Issuance of shares related to restricted stock (in shares)		1,000
Issuance of shares related to restricted stock	0
Treasury share repurchases (in shares)				1,000
Treasury share repurchases	(16)			$ (16)
Net income	51,951					51,951
Comprehensive income	6,970				6,970
Common stock, ending balance (in shares) at Dec. 31, 2022		54,852,000
Equity, ending balance at Dec. 31, 2022	1,686,863	$ 548	532,508	$ (189,114)	(29,489)	1,372,410
Treasury stock, ending balance (in shares) at Dec. 31, 2022				5,165,000
Common stock, beginning balance (in shares) at Mar. 31, 2023		54,857,000
Equity, beginning balance at Mar. 31, 2023	$ 1,447,084	$ 548	535,356	$ (189,114)	(31,564)	1,131,858
Treasury stock, beginning balance (in shares) at Mar. 31, 2023	5,165,000			5,165,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 10,283		10,283
Exercise of stock options (in shares)	268,900	269,000
Exercise of stock options	$ 10,818	$ 3	10,815
Issuance of shares related to restricted stock (in shares)		203,000
Issuance of shares related to restricted stock	0	$ 2	(2)
Treasury share repurchases (in shares)				515,000
Treasury share repurchases	(30,524)			$ (30,524)
Net income	159,881					159,881
Comprehensive income	3,035				3,035
Common stock, ending balance (in shares) at Dec. 31, 2023		55,329,000
Equity, ending balance at Dec. 31, 2023	$ 1,600,577	$ 553	556,452	$ (219,638)	(28,529)	1,291,739
Treasury stock, ending balance (in shares) at Dec. 31, 2023	5,680,000			5,680,000
Common stock, beginning balance (in shares) at Sep. 30, 2023		55,291,000
Equity, beginning balance at Sep. 30, 2023	$ 1,535,959	$ 552	552,369	$ (219,661)	(35,994)	1,238,693
Treasury stock, beginning balance (in shares) at Sep. 30, 2023				5,680,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,449		2,449
Exercise of stock options (in shares)		38,000
Exercise of stock options	1,635	$ 1	1,634
Treasury share repurchases	23			$ 23
Net income	53,046					53,046
Comprehensive income	7,465				7,465
Common stock, ending balance (in shares) at Dec. 31, 2023		55,329,000
Equity, ending balance at Dec. 31, 2023	$ 1,600,577	$ 553	$ 556,452	$ (219,638)	$ (28,529)	$ 1,291,739
Treasury stock, ending balance (in shares) at Dec. 31, 2023	5,680,000			5,680,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Activities
Net income	$ 159,881	$ 158,246
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	22,832	24,762
Loss on disposal of property and equipment	231	171
Deferred income taxes	14,892	14,021
Amortization of debt origination costs	3,726	2,613
Stock-based compensation costs	10,283	9,756
Non-cash operating lease cost	4,494	4,697
Other	0	447
Changes in operating assets and liabilities:
Accounts receivable	(7,017)	(17,078)
Inventories	13,790	(38,587)
Prepaid expenses and other current assets	(2,605)	(596)
Accounts payable	(23,964)	8,892
Accrued liabilities	(7,732)	8,345
Operating lease liabilities	(5,259)	(4,941)
Other	(1,533)	(19)
Net cash provided by operating activities	182,019	170,729
Investing Activities
Purchases of property, plant and equipment	(6,407)	(5,226)
Other	1,300	0
Net cash used in investing activities	(5,107)	(5,226)
Financing Activities
Term loan repayments	(150,000)	(55,000)
Borrowings under revolving credit agreement	0	20,000
Repayments under revolving credit agreement	0	(20,000)
Payments of debt costs	(769)	0
Payments of finance leases	(2,112)	(2,058)
Proceeds from exercise of stock options	10,818	7,173
Fair value of shares surrendered as payment of tax withholding	(5,508)	(5,466)
Repurchase of common stock	(25,000)	(50,000)
Net cash used in financing activities	(172,571)	(105,351)
Effects of exchange rate changes on cash and cash equivalents	785	(979)
Increase in cash and cash equivalents	5,126	59,173
Cash and cash equivalents - beginning of period	58,489	27,185
Cash and cash equivalents - end of period	63,615	86,358
Supplemental Cash Flow Information
Interest paid	49,666	36,716
Income taxes paid	$ 38,606	$ 27,632

Business and Basis of Presentat

Business and Basis of Presentation	9 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Nature of Business Prestige Consumer Healthcare Inc. (referred to herein as the “Company” or “we,” which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Consumer Healthcare Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (“OTC”) healthcare products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Prestige Consumer Healthcare Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 7 to these Condensed Consolidated Financial Statements. Economic Environment There has been economic uncertainty in the United States and globally due to several factors, including global supply chain constraints, rising interest rates, a high inflationary environment and geopolitical events. We expect economic conditions will continue to be highly volatile and uncertain, put pressure on prices and supply, and could affect demand for our products. We have continued to see changes in the purchasing patterns of our consumers, including a reduction in the frequency of visits to retailers and a shift in many markets to purchasing our products online. The volatile environment has impacted the supply of labor and raw materials and exacerbated rising input costs. Although we have not experienced a material disruption to our overall supply chain to date, we have and may continue to experience shortages, delays and backorders for certain ingredients and products, difficulty scheduling shipping for our products, as well as price increases from many of our suppliers for both shipping and product costs. In addition, labor shortages have impacted our manufacturing operations and may impact our ability to supply certain products to our customers. To date, these global conditions have not had a material negative impact on our operations, supply chain, overall costs or demand for most of our products or resulting aggregate sales and earnings, and, as such, it has also not materially negatively impacted our liquidity position. We continue to generate operating cash flows to meet our short-term liquidity needs. These circumstances could change, however, in this dynamic environment. If conditions cause further disruption in the global supply chain, the availability of labor and materials or otherwise further increase costs, it may materially affect our operations and those of third parties on which we rely, including causing material disruptions in the supply and distribution of our products. The extent to which these conditions impact our results and liquidity will depend on future developments, which are highly uncertain and cannot be predicted, including global supply chain constraints, inflation, global conflicts and instability, and the potential for further outbreaks of severe illnesses. These effects could have a material adverse impact on our business, liquidity, capital resources, and results of operations and those of the third parties on which we rely. Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2024) mean our fiscal year ending or ended on March 31st of that year. Operating results for the nine months ended December 31, 2023 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2024. These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions. Recently Adopted Accounting Pronouncements In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires entities to apply Topic 606 to recognize and measure contract assets and liabilities in a business combination. This ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We adopted this standard effective April 1, 2023. The impact of the adoption of this new standard will depend on the magnitude of future acquisitions. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and also issued subsequent amendments to the initial guidance (collectively, "Topic 848"). In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848 , which extends the period of time preparers can utilize the reference rate reform relief guidance in Topic 848. Topic 848 provides optional guidance for contract modifications and certain hedging relationships associated with the transition from reference rates that are expected to be discontinued. On April 4, 2023, we entered into Amendment No. 8 ("ABL Amendment No. 8") to the Company's asset-based revolving credit facility originally entered into on January 31, 2012 (the "2012 ABL Revolver"). ABL Amendment No. 8 provides for the replacement of LIBOR with Secured Overnight Financing Rate ("SOFR") as our reference rate. On June 12, 2023, we entered into Amendment No. 7 ("Term Loan Amendment No. 7") to the Company’s term loan originally entered into on January 31, 2012 (the “2012 Term Loan”), effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate. Effective July 1, 2023, we have transitioned all discontinued reference rates to SOFR. The adoption of Topic 848 did not have a material impact on our Consolidated Financial Statements. Recently Issued Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . The amendments in this update require that entities disclose, on an annual basis, specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The amendments in this update also require disclosure, on an annual basis, of income taxes paid, disaggregated by federal, state and foreign taxes and disaggregated by individual jurisdictions in which income taxes paid are equal to or greater than five percent of total income taxes paid. In addition, the amendments in this update also require that income (or loss) before income taxes be disaggregated between domestic and foreign and income tax expense (or benefit) be disaggregated by federal, state and foreign. This ASU is effective for annual periods beginning after December 15, 2024. We are currently evaluating the impact that this ASU may have on our consolidated financial statement disclosures. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . The amendments in this update intend to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, the addition of a category for other segment items by reportable segment, that all annual segment disclosures be disclosed in interim periods, and other related segment disclosures. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the impact that this ASU may have on our consolidated financial statement disclosures.

Inventories

Inventories	9 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: (In thousands) December 31, 2023 March 31, 2023 Components of Inventories Packaging and raw materials $ 22,093 $ 20,634 Work in process 555 220 Finished goods 125,989 141,267 Inventories $ 148,637 $ 162,121

Goodwill

Goodwill	9 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC International OTC Consolidated Balance - March 31, 2023 Goodwill $ 711,452 $ 30,204 $ 741,656 Accumulated impairment loss (212,516) (1,587) (214,103) Balance - March 31, 2023 498,936 28,617 527,553 Effects of foreign currency exchange rates — 325 325 Balance - December 31, 2023 Goodwill 711,452 30,529 741,981 Accumulated impairment loss (212,516) (1,587) (214,103) Balance - December 31, 2023 $ 498,936 $ 28,942 $ 527,878 The date of our annual impairment review was February 28, 2023, and we recorded impairment charges to goodwill of $48.8 million in our March 31, 2023 financial statements. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties related to future sales, gross margins, and advertising and marketing expenses, which can be impacted by increases in competition, changing consumer preferences, technical advances, supply chain constraints, labor shortages, and inflation. The discount rate assumption may be influenced by such factors as changes in interest rates and rates of inflation, which can have an impact on the determination of fair value. If these assumptions are adversely affected, we may be required to record impairment charges in the future. As of December 31, 2023, we determined no events have occurred that would indicate potential impairment of goodwill.

Intangible Assets, net

Intangible Assets, net	9 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2023 $ 2,168,902 $ 411,118 $ 2,580,020 Effects of foreign currency exchange rates 1,223 334 1,557 Balance — December 31, 2023 $ 2,170,125 $ 411,452 $ 2,581,577 Accumulated Amortization Balance — March 31, 2023 $ — $ 238,127 $ 238,127 Additions — 14,842 14,842 Effects of foreign currency exchange rates — 79 79 Balance — December 31, 2023 $ — $ 253,048 $ 253,048 Intangible assets, net - December 31, 2023 $ 2,170,125 $ 158,404 $ 2,328,529 Amortization expense was $4.9 million and $14.8 million for the three and nine months ended December 31, 2023, respectively, and $5.6 million and $16.9 million for the three and nine months ended December 31, 2022, respectively. Finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 25 years, and the estimated amortization expense for each of the five succeeding years and the periods thereafter is as follows (in thousands): (In thousands) Year Ending March 31, Amount 2024 (remaining three months ended March 31, 2024) $ 4,947 2025 18,115 2026 16,165 2027 14,574 2028 12,237 Thereafter 92,366 $ 158,404 The date of our annual impairment review was February 28, 2023, and we recorded impairment charges to intangible assets of $321.4 million in our March 31, 2023 financial statements. The assumptions subject to significant uncertainties in the impairment analysis include the discount rate utilized in the analysis, as well as future sales, gross margins, and advertising and marketing expenses. The discount rate assumption may be influenced by such factors as changes in interest rates and rates of inflation, which can have an impact on the determination of fair value. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer needs or preferences, technological advances, changes in advertising and marketing expenses, or the potential impacts of supply chain constraints, labor shortages, or inflation, we may be required to record impairment charges in the future. As of December 31, 2023, no events have occurred that would indicate potential impairment of intangible assets.

Leases

Leases	9 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Leases	Leases We lease real estate and equipment for use in our operations. The components of lease expense for the three and nine months ended December 31, 2023 and 2022 were as follows: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2023 2022 2023 2022 Finance lease cost: Amortization of right-of-use assets $ 665 $ 665 $ 1,994 $ 1,994 Interest on lease liabilities 20 41 74 136 Operating lease cost 1,624 1,621 4,872 4,872 Short term lease cost 34 35 101 120 Variable lease cost 14,488 14,727 47,885 43,742 Total net lease cost $ 16,831 $ 17,089 $ 54,926 $ 50,864 As of December 31, 2023, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2024 (remaining three months ending March 31, 2024) $ 1,806 $ 731 $ 2,537 2025 4,834 1,509 6,343 2026 2,348 96 2,444 2027 1,916 80 1,996 2028 1,437 — 1,437 Thereafter 265 — 265 Total undiscounted lease payments 12,606 2,416 15,022 Less amount of lease payments representing interest (818) (33) (851) Total present value of lease payments $ 11,788 $ 2,383 $ 14,171 The weighted average remaining lease term and weighted average discount rate were as follows: December 31, 2023 Weighted average remaining lease term (years) Operating leases 2.95 Finance leases 1.03 Weighted average discount rate Operating leases 3.80 % Finance leases 2.93 %
Leases	Leases We lease real estate and equipment for use in our operations. The components of lease expense for the three and nine months ended December 31, 2023 and 2022 were as follows: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2023 2022 2023 2022 Finance lease cost: Amortization of right-of-use assets $ 665 $ 665 $ 1,994 $ 1,994 Interest on lease liabilities 20 41 74 136 Operating lease cost 1,624 1,621 4,872 4,872 Short term lease cost 34 35 101 120 Variable lease cost 14,488 14,727 47,885 43,742 Total net lease cost $ 16,831 $ 17,089 $ 54,926 $ 50,864 As of December 31, 2023, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2024 (remaining three months ending March 31, 2024) $ 1,806 $ 731 $ 2,537 2025 4,834 1,509 6,343 2026 2,348 96 2,444 2027 1,916 80 1,996 2028 1,437 — 1,437 Thereafter 265 — 265 Total undiscounted lease payments 12,606 2,416 15,022 Less amount of lease payments representing interest (818) (33) (851) Total present value of lease payments $ 11,788 $ 2,383 $ 14,171 The weighted average remaining lease term and weighted average discount rate were as follows: December 31, 2023 Weighted average remaining lease term (years) Operating leases 2.95 Finance leases 1.03 Weighted average discount rate Operating leases 3.80 % Finance leases 2.93 %

Other Accrued Liabilities

Other Accrued Liabilities	9 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other Accrued Liabilities Other accrued liabilities consist of the following: (In thousands) December 31, 2023 March 31, 2023 Accrued marketing costs $ 29,648 $ 30,471 Accrued compensation costs 9,940 14,292 Accrued broker commissions 1,888 1,767 Income taxes payable 5,953 10,645 Accrued professional fees 5,100 4,254 Accrued production costs 4,568 5,700 Other accrued liabilities 7,966 5,395 $ 65,063 $ 72,524

Long-Term Debt

Long-Term Debt	9 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) December 31, 2023 March 31, 2023 2021 Senior Notes bearing interest at 3.750%, with interest payable on April 1 and October 1 of each year. The 2021 Senior Notes mature on April 1, 2031. $ 600,000 $ 600,000 2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028. 400,000 400,000 2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.50%, or an alternate base rate plus a margin of 1.00% per annum (at March 31, 2023) and SOFR plus a margin of 2.00% plus a credit spread adjustment (at December 31, 2023), due on July 1, 2028. 210,000 360,000 Long-term debt 1,210,000 1,360,000 Less: unamortized debt costs (10,660) (14,212) Long-term debt, net $ 1,199,340 $ 1,345,788 At December 31, 2023, we had no balance outstanding on the 2012 ABL Revolver and a borrowing capacity of $168.9 million. On April 4, 2023, we entered into ABL Amendment No. 8. ABL Amendment No. 8 provides for the replacement of LIBOR with SOFR as our reference rate for the 2012 ABL Revolver. On June 12, 2023, we entered into Term Loan Amendment No. 7, effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate for the 2012 Term Loan. On December 8, 2023, we entered into Amendment No. 9 ("ABL Amendment No. 9") to the 2012 ABL Revolver. ABL Amendment No. 9 provides for (i) an increase in the aggregate revolving commitment of the facility from $175.0 million to $200.0 million, (ii) an extension of the maturity date of the 2012 ABL Revolver to December 8, 2028, and (iii) increased flexibility under the credit agreement governing the 2012 ABL Revolver, including, but not limited to, increased flexibility related to restricted payments, debt incurrence and borrowing base calculations. There were no changes to interest terms as a result of this amendment. As of December 31, 2023, aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans under the 2012 Term Loan, the 2012 ABL Revolver and the indentures governing the senior unsecured notes due 2031 (the "2021 Senior Notes") and the senior unsecured notes due 2028 (the "2019 Senior Notes") are as follows: (In thousands) Year Ending March 31, Amount 2024 (remaining three months ending March 31, 2024) $ — 2025 — 2026 — 2027 — 2028 400,000 Thereafter 810,000 $ 1,210,000

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. FASB Accounting Standards Codification ("ASC") 820, Fair Value Measurements , requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. ASC 820 established market (observable inputs) as the preferred source of fair value, to be followed by our assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by us using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2021 Senior Notes, the 2019 Senior Notes, the 2012 Term B-5 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. The summary below details the carrying amounts and estimated fair values of these instruments at December 31, 2023 and March 31, 2023. December 31, 2023 March 31, 2023 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2019 Senior Notes 400,000 391,000 400,000 383,500 2021 Senior Notes 600,000 523,500 600,000 510,750 2012 Term B-5 Loans 210,000 210,263 360,000 359,550

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Dec. 31, 2023
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity We are authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends. No dividends have been declared or paid on our common stock through December 31, 2023. On May 2, 2023, the Company's Board of Directors authorized the repurchase of up to $25.0 million of the Company's issued and outstanding common stock through May 31, 2024, utilizing open market transactions, transactions structured through investment banking institutions, in privately-negotiated transactions, by direct purchases of common stock or a combination of the foregoing in compliance with the applicable rules and regulations of the U.S. Securities and Exchange Commission. We completed the repurchase in the first quarter of fiscal 2024. During the three and nine months ended December 31, 2023 and 2022, we repurchased shares of our common stock and recorded them as treasury stock. Our share repurchases consisted of the following: Three Months Ended December 31, Nine Months Ended December 31, 2023 2022 2023 2022 Shares repurchased pursuant to the provisions of the various employee restricted stock awards: Number of shares — 303 88,953 99,522 Average price per share $ — $50.63 $61.92 $54.92 Total amount repurchased $ — $0.02 million $5.5 million $5.5 million Shares repurchased in conjunction with our share repurchase program: Number of shares — — 426,479 914,236 Average price per share $ — $ — $58.62 $54.69 Total amount repurchased $ — $ — $25.0 million $50.0 million

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Dec. 31, 2023
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Accumulated other comprehensive loss consisted of the following at December 31, 2023 and March 31, 2023: (In thousands) December 31, 2023 March 31, 2023 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (29,245) $ (32,280) Unrecognized net gain on pension plans, net of tax of $(214) and $(214), respectively 716 716 Accumulated other comprehensive loss, net of tax $ (28,529) $ (31,564)

Earnings Per Share

Earnings Per Share	9 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2023 2022 2023 2022 Numerator Net income $ 53,046 $ 51,951 $ 159,881 $ 158,246 Denominator Denominator for basic earnings per share — weighted average shares outstanding 49,740 49,693 49,731 49,919 Dilutive effect of unvested restricted stock units and options issued to employees and directors 385 493 403 473 Denominator for diluted earnings per share 50,125 50,186 50,134 50,392 Earnings per Common Share: Basic earnings per share $ 1.07 $ 1.05 $ 3.21 $ 3.17 Diluted earnings per share $ 1.06 $ 1.04 $ 3.19 $ 3.14

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “2005 Plan”), which provided for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units ("RSUs") and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, our stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the 2005 Plan, among other changes. On June 23, 2020, the Board of Directors adopted the Prestige Consumer Healthcare Inc. 2020 Long-Term Incentive Plan (the “2020 Plan”). The 2020 Plan became effective on August 4, 2020, upon the approval of the 2020 Plan by our stockholders. On June 23, 2020, a total of 2,827,210 shares were available for issuance under the 2020 Plan (comprised of 2,000,000 new shares plus 827,210 shares that were unissued under the 2005 Plan). Since the 2020 Plan became effective, all equity awards have been made from the 2020 Plan, and the Company will not grant any additional awards under the 2005 Plan. The following table provides information regarding our stock-based compensation: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2023 2022 2023 2022 Pre-tax stock-based compensation costs charged against income $ 2,449 $ 2,433 $ 10,283 $ 9,756 Income tax benefit recognized on compensation costs $ 241 $ 49 $ 910 $ 924 Total fair value of options and RSUs vested during the period $ — $ 63 $ 12,213 $ 10,352 Cash received from the exercise of stock options $ 1,635 $ 5,684 $ 10,818 $ 7,173 Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises $ 351 $ 731 $ 1,490 $ 3,626 At December 31, 2023, there were $3.1 million of unrecognized compensation costs related to unvested stock options under the 2005 Plan and the 2020 Plan, excluding an estimate for forfeitures which may occur. We expect to recognize such costs over a weighted average period of 1.9 years. At December 31, 2023, there were $12.9 million of unrecognized compensation costs related to unvested RSUs and performance stock units ("PSUs") under the 2005 Plan and the 2020 Plan, excluding an estimate for forfeitures which may occur. We expect to recognize such costs over a weighted average period of 1.7 years. At December 31, 2023, there were 1.9 million shares available for issuance under the 2020 Plan. Restricted Stock Units The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant. A summary of the RSUs granted under the 2005 Plan and the 2020 Plan is presented below: RSUs Shares (in thousands) Weighted Nine Months Ended December 31, 2022 Unvested at March 31, 2022 440.9 $ 38.45 Granted 151.0 55.03 Incremental performance shares 42.4 — Vested (223.4) 32.09 Forfeited (1.9) 49.51 Unvested at December 31, 2022 409.0 47.17 Vested at December 31, 2022 108.5 36.54 Nine Months Ended December 31, 2023 Unvested at March 31, 2023 409.0 $ 47.17 Granted 157.1 62.06 Incremental performance shares 41.4 — Vested (205.0) 43.17 Forfeited (10.6) 52.68 Unvested at December 31, 2023 391.9 54.43 Vested at December 31, 2023 110.2 38.77 Options The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions presented below: Nine Months Ended December 31, 2023 2022 Expected volatility 30.2% - 31.6% 30.8% - 30.9% Expected dividends $ — $ — Expected term in years 6.0 to 7.0 6.0 to 7.0 Risk-free rate 3.6% to 4.1% 2.8% to 2.9% Weighted average grant date fair value of options granted $ 23.79 $ 20.10 A summary of option activity under the 2005 Plan and the 2020 Plan is as follows: Options Shares (in thousands) Weighted Weighted Aggregate Nine Months Ended December 31, 2022 Outstanding at March 31, 2022 1,100.9 $ 40.62 Granted 197.6 54.48 Exercised (200.2) 35.82 Forfeited (10.3) 49.53 Expired (0.8) 44.33 Outstanding at December 31, 2022 1,087.2 43.94 6.7 $ 20,289 Vested at December 31, 2022 670.5 41.18 5.4 $ 14,360 Nine Months Ended December 31, 2023 Outstanding at March 31, 2023 1,081.0 $ 43.96 Granted 131.1 61.81 Exercised (268.9) 40.23 Forfeited (41.0) 54.15 Expired (2.8) 54.47 Outstanding at December 31, 2023 899.4 47.18 6.2 $ 12,703 Vested at December 31, 2023 606.2 43.23 5.0 $ 10,903 The aggregate intrinsic value of options exercised during the nine months ended December 31, 2023 was $5.4 million.

Income Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rates used in the calculation of income taxes were 23.8% and 23.7% for the three months ended December 31, 2023 and 2022, respectively. The effective tax rates used in the calculation of income taxes were 23.4% and 23.0% for the nine months ended December 31, 2023 and 2022, respectively. The increase in the effective tax rate for the three months ended December 31, 2023, compared to the three months ended December 31, 2022, was due to discrete items primarily pertaining to stock-based compensation. The increase in the effective tax rate for the nine months ended December 31, 2023, compared to the nine months ended December 31, 2022, was due to discrete items primarily pertaining to stock-based compensation and state tax rate legislative changes.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We are involved from time to time in legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the reasonably possible losses from resolution of routine legal matters and other claims incidental to our business will not have a material effect on our financial statements.

Concentrations of Risk

Concentrations of Risk	9 Months Ended
	Dec. 31, 2023
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the area of OTC Healthcare. We sell our products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels. During the three and nine months ended December 31, 2023, approximately 37.0% and 37.8%, respectively, of our gross revenues were derived from our five top selling brands. During the three and nine months ended December 31, 2022, approximately 36.9% and 38.7%, respectively, of our gross revenues were derived from our five top selling brands. Walmart accounted for approximately 19.0% and 19.6%, respectively, of our gross revenues for the three and nine months ended December 31, 2023. Walmart accounted for approximately 19.9% and 19.8%, respectively, of our gross revenues for the three and nine months ended December 31, 2022. Amazon accounted for approximately 10.7% and 10.4%, respectively, of gross revenues for the three and nine months ended December 31, 2023. Our product distribution in the United States is managed by a third party through one primary distribution center in Clayton, Indiana. In addition, we operate one manufacturing facility for certain of our products located in Lynchburg, Virginia, which manufactures many of the Summer's Eve and Fleet products. A natural disaster, such as tornado, earthquake, flood, or fire, could damage our inventory and/or materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. In addition, a serious disruption caused by performance or contractual issues with our third-party distribution manager or labor shortages or public health emergencies at our distribution center or manufacturing facility could materially impact our product distribution. Any disruption could result in increased costs, expense and/or shipping times, and could cause us to incur customer fees and penalties. We could also incur significantly higher costs and experience longer lead times if we need to replace our distribution center, the third-party distribution manager or the manufacturing facility. As a result, any serious disruption could have a material adverse effect on our business, financial condition and results of operations. At December 31, 2023, we had relationships with 129 third-party manufacturers. Of those, we had long-term contracts with 27 manufacturers that produced items that accounted for approximately 72.1% of gross sales for the nine months ended December 31, 2023. At December 31, 2022, we had relationships with 133 third-party manufacturers. Of those, we had long-term contracts with 27 manufacturers that produced items that accounted for approximately 70.5% of gross sales for the nine months ended December 31, 2022. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results of operations. Although we are continually in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

Business Segments	9 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Business Segments	Business Segments Our current reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and marketing expenses. The tables below summarize information about our reportable segments. Three Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 236,565 $ 46,176 $ 282,741 Cost of sales 106,090 18,713 124,803 Gross profit 130,475 27,463 157,938 Advertising and marketing 33,917 5,549 39,466 Contribution margin $ 96,558 $ 21,914 $ 118,472 Other operating expenses 31,640 Operating income $ 86,832 * Intersegment revenues of $0.5 million were eliminated from the North American OTC Healthcare segment. Nine Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 727,131 $ 121,235 $ 848,366 Cost of sales 323,632 52,103 375,735 Gross profit 403,499 69,132 472,631 Advertising and marketing 100,707 15,092 115,799 Contribution margin $ 302,792 $ 54,040 $ 356,832 Other operating expenses 96,556 Operating income $ 260,276 * Intersegment revenues of $2.5 million were eliminated from the North American OTC Healthcare segment. Three Months Ended December 31, 2022 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 236,884 $ 38,640 $ 275,524 Cost of sales 110,554 14,568 125,122 Gross profit 126,330 24,072 150,402 Advertising and marketing 24,831 5,592 30,423 Contribution margin $ 101,499 $ 18,480 $ 119,979 Other operating expenses 32,795 Operating income $ 87,184 * Intersegment revenues of $1.1 million were eliminated from the North American OTC Healthcare segment. Nine Months Ended December 31, 2022 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 731,456 $ 110,400 $ 841,856 Cost of sales 327,008 43,318 370,326 Gross profit 404,448 67,082 471,530 Advertising and marketing 99,559 14,634 114,193 Contribution margin $ 304,889 $ 52,448 $ 357,337 Other operating expenses 98,755 Operating income $ 258,582 * Intersegment revenues of $2.8 million were eliminated from the North American OTC Healthcare segment. The tables below summarize information about our segment revenues from similar product groups. Three Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Analgesics $ 28,680 $ 1,586 $ 30,266 Cough & Cold 27,359 5,814 33,173 Women's Health 53,076 5,190 58,266 Gastrointestinal 38,919 22,707 61,626 Eye & Ear Care 38,503 6,569 45,072 Dermatologicals 26,603 1,165 27,768 Oral Care 20,362 3,100 23,462 Other OTC 3,063 45 3,108 Total segment revenues $ 236,565 $ 46,176 $ 282,741 Nine Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Analgesics $ 85,838 $ 3,814 $ 89,652 Cough & Cold 73,703 19,129 92,832 Women's Health 163,031 17,218 180,249 Gastrointestinal 122,303 49,678 171,981 Eye & Ear Care 117,719 17,715 135,434 Dermatologicals 94,299 3,972 98,271 Oral Care 61,400 9,591 70,991 Other OTC 8,838 118 8,956 Total segment revenues $ 727,131 $ 121,235 $ 848,366 Three Months Ended December 31, 2022 (In thousands) North American OTC International OTC Consolidated Analgesics $ 29,396 $ 648 $ 30,044 Cough & Cold 31,246 6,336 37,582 Women's Health 53,918 4,138 58,056 Gastrointestinal 38,194 18,555 56,749 Eye & Ear Care 32,653 5,229 37,882 Dermatologicals 27,223 978 28,201 Oral Care 21,371 2,738 24,109 Other OTC 2,883 18 2,901 Total segment revenues $ 236,884 $ 38,640 $ 275,524 Nine Months Ended December 31, 2022 (In thousands) North American OTC International OTC Consolidated Analgesics $ 89,943 $ 1,642 $ 91,585 Cough & Cold 76,896 19,775 96,671 Women's Health 174,481 13,750 188,231 Gastrointestinal 119,533 48,619 168,152 Eye & Ear Care 109,225 14,699 123,924 Dermatologicals 89,550 2,886 92,436 Oral Care 63,597 8,988 72,585 Other OTC 8,231 41 8,272 Total segment revenues $ 731,456 $ 110,400 $ 841,856

Business and Basis of Present_2

Business and Basis of Presentation (Policies)	9 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2024) mean our fiscal year ending or ended on March 31st of that year. Operating results for the nine months ended December 31, 2023 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2024. These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023.
Use of Estimates	Use of Estimates
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires entities to apply Topic 606 to recognize and measure contract assets and liabilities in a business combination. This ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We adopted this standard effective April 1, 2023. The impact of the adoption of this new standard will depend on the magnitude of future acquisitions. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and also issued subsequent amendments to the initial guidance (collectively, "Topic 848"). In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848 , which extends the period of time preparers can utilize the reference rate reform relief guidance in Topic 848. Topic 848 provides optional guidance for contract modifications and certain hedging relationships associated with the transition from reference rates that are expected to be discontinued. On April 4, 2023, we entered into Amendment No. 8 ("ABL Amendment No. 8") to the Company's asset-based revolving credit facility originally entered into on January 31, 2012 (the "2012 ABL Revolver"). ABL Amendment No. 8 provides for the replacement of LIBOR with Secured Overnight Financing Rate ("SOFR") as our reference rate. On June 12, 2023, we entered into Amendment No. 7 ("Term Loan Amendment No. 7") to the Company’s term loan originally entered into on January 31, 2012 (the “2012 Term Loan”), effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate. Effective July 1, 2023, we have transitioned all discontinued reference rates to SOFR. The adoption of Topic 848 did not have a material impact on our Consolidated Financial Statements. Recently Issued Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . The amendments in this update require that entities disclose, on an annual basis, specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The amendments in this update also require disclosure, on an annual basis, of income taxes paid, disaggregated by federal, state and foreign taxes and disaggregated by individual jurisdictions in which income taxes paid are equal to or greater than five percent of total income taxes paid. In addition, the amendments in this update also require that income (or loss) before income taxes be disaggregated between domestic and foreign and income tax expense (or benefit) be disaggregated by federal, state and foreign. This ASU is effective for annual periods beginning after December 15, 2024. We are currently evaluating the impact that this ASU may have on our consolidated financial statement disclosures. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . The amendments in this update intend to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, the addition of a category for other segment items by reportable segment, that all annual segment disclosures be disclosed in interim periods, and other related segment disclosures. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the impact that this ASU may have on our consolidated financial statement disclosures.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories consist of the following: (In thousands) December 31, 2023 March 31, 2023 Components of Inventories Packaging and raw materials $ 22,093 $ 20,634 Work in process 555 220 Finished goods 125,989 141,267 Inventories $ 148,637 $ 162,121

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Goodwill	A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC International OTC Consolidated Balance - March 31, 2023 Goodwill $ 711,452 $ 30,204 $ 741,656 Accumulated impairment loss (212,516) (1,587) (214,103) Balance - March 31, 2023 498,936 28,617 527,553 Effects of foreign currency exchange rates — 325 325 Balance - December 31, 2023 Goodwill 711,452 30,529 741,981 Accumulated impairment loss (212,516) (1,587) (214,103) Balance - December 31, 2023 $ 498,936 $ 28,942 $ 527,878

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	9 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Finite-Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2023 $ 2,168,902 $ 411,118 $ 2,580,020 Effects of foreign currency exchange rates 1,223 334 1,557 Balance — December 31, 2023 $ 2,170,125 $ 411,452 $ 2,581,577 Accumulated Amortization Balance — March 31, 2023 $ — $ 238,127 $ 238,127 Additions — 14,842 14,842 Effects of foreign currency exchange rates — 79 79 Balance — December 31, 2023 $ — $ 253,048 $ 253,048 Intangible assets, net - December 31, 2023 $ 2,170,125 $ 158,404 $ 2,328,529
Reconciliation of the Activity Affecting Indefinite-Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2023 $ 2,168,902 $ 411,118 $ 2,580,020 Effects of foreign currency exchange rates 1,223 334 1,557 Balance — December 31, 2023 $ 2,170,125 $ 411,452 $ 2,581,577 Accumulated Amortization Balance — March 31, 2023 $ — $ 238,127 $ 238,127 Additions — 14,842 14,842 Effects of foreign currency exchange rates — 79 79 Balance — December 31, 2023 $ — $ 253,048 $ 253,048 Intangible assets, net - December 31, 2023 $ 2,170,125 $ 158,404 $ 2,328,529
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 25 years, and the estimated amortization expense for each of the five succeeding years and the periods thereafter is as follows (in thousands): (In thousands) Year Ending March 31, Amount 2024 (remaining three months ended March 31, 2024) $ 4,947 2025 18,115 2026 16,165 2027 14,574 2028 12,237 Thereafter 92,366 $ 158,404

Leases (Tables)

Leases (Tables)	9 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Components of Lease Expense	The components of lease expense for the three and nine months ended December 31, 2023 and 2022 were as follows: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2023 2022 2023 2022 Finance lease cost: Amortization of right-of-use assets $ 665 $ 665 $ 1,994 $ 1,994 Interest on lease liabilities 20 41 74 136 Operating lease cost 1,624 1,621 4,872 4,872 Short term lease cost 34 35 101 120 Variable lease cost 14,488 14,727 47,885 43,742 Total net lease cost $ 16,831 $ 17,089 $ 54,926 $ 50,864 The weighted average remaining lease term and weighted average discount rate were as follows: December 31, 2023 Weighted average remaining lease term (years) Operating leases 2.95 Finance leases 1.03 Weighted average discount rate Operating leases 3.80 % Finance leases 2.93 %
Maturities of Operating Leases	As of December 31, 2023, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2024 (remaining three months ending March 31, 2024) $ 1,806 $ 731 $ 2,537 2025 4,834 1,509 6,343 2026 2,348 96 2,444 2027 1,916 80 1,996 2028 1,437 — 1,437 Thereafter 265 — 265 Total undiscounted lease payments 12,606 2,416 15,022 Less amount of lease payments representing interest (818) (33) (851) Total present value of lease payments $ 11,788 $ 2,383 $ 14,171
Maturities of Finance Leases	As of December 31, 2023, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2024 (remaining three months ending March 31, 2024) $ 1,806 $ 731 $ 2,537 2025 4,834 1,509 6,343 2026 2,348 96 2,444 2027 1,916 80 1,996 2028 1,437 — 1,437 Thereafter 265 — 265 Total undiscounted lease payments 12,606 2,416 15,022 Less amount of lease payments representing interest (818) (33) (851) Total present value of lease payments $ 11,788 $ 2,383 $ 14,171

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	9 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other accrued liabilities consist of the following: (In thousands) December 31, 2023 March 31, 2023 Accrued marketing costs $ 29,648 $ 30,471 Accrued compensation costs 9,940 14,292 Accrued broker commissions 1,888 1,767 Income taxes payable 5,953 10,645 Accrued professional fees 5,100 4,254 Accrued production costs 4,568 5,700 Other accrued liabilities 7,966 5,395 $ 65,063 $ 72,524

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) December 31, 2023 March 31, 2023 2021 Senior Notes bearing interest at 3.750%, with interest payable on April 1 and October 1 of each year. The 2021 Senior Notes mature on April 1, 2031. $ 600,000 $ 600,000 2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028. 400,000 400,000 2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.50%, or an alternate base rate plus a margin of 1.00% per annum (at March 31, 2023) and SOFR plus a margin of 2.00% plus a credit spread adjustment (at December 31, 2023), due on July 1, 2028. 210,000 360,000 Long-term debt 1,210,000 1,360,000 Less: unamortized debt costs (10,660) (14,212) Long-term debt, net $ 1,199,340 $ 1,345,788
Aggregate Future Principal Payments	As of December 31, 2023, aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans under the 2012 Term Loan, the 2012 ABL Revolver and the indentures governing the senior unsecured notes due 2031 (the "2021 Senior Notes") and the senior unsecured notes due 2028 (the "2019 Senior Notes") are as follows: (In thousands) Year Ending March 31, Amount 2024 (remaining three months ending March 31, 2024) $ — 2025 — 2026 — 2027 — 2028 400,000 Thereafter 810,000 $ 1,210,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Summary of Carry Amounts and Fair Value Measurements	The summary below details the carrying amounts and estimated fair values of these instruments at December 31, 2023 and March 31, 2023. December 31, 2023 March 31, 2023 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2019 Senior Notes 400,000 391,000 400,000 383,500 2021 Senior Notes 600,000 523,500 600,000 510,750 2012 Term B-5 Loans 210,000 210,263 360,000 359,550

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Dec. 31, 2023
Stockholders' Equity Note [Abstract]
Class of Treasury Stock	Our share repurchases consisted of the following: Three Months Ended December 31, Nine Months Ended December 31, 2023 2022 2023 2022 Shares repurchased pursuant to the provisions of the various employee restricted stock awards: Number of shares — 303 88,953 99,522 Average price per share $ — $50.63 $61.92 $54.92 Total amount repurchased $ — $0.02 million $5.5 million $5.5 million Shares repurchased in conjunction with our share repurchase program: Number of shares — — 426,479 914,236 Average price per share $ — $ — $58.62 $54.69 Total amount repurchased $ — $ — $25.0 million $50.0 million

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Dec. 31, 2023
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss consisted of the following at December 31, 2023 and March 31, 2023: (In thousands) December 31, 2023 March 31, 2023 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (29,245) $ (32,280) Unrecognized net gain on pension plans, net of tax of $(214) and $(214), respectively 716 716 Accumulated other comprehensive loss, net of tax $ (28,529) $ (31,564)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2023 2022 2023 2022 Numerator Net income $ 53,046 $ 51,951 $ 159,881 $ 158,246 Denominator Denominator for basic earnings per share — weighted average shares outstanding 49,740 49,693 49,731 49,919 Dilutive effect of unvested restricted stock units and options issued to employees and directors 385 493 403 473 Denominator for diluted earnings per share 50,125 50,186 50,134 50,392 Earnings per Common Share: Basic earnings per share $ 1.07 $ 1.05 $ 3.21 $ 3.17 Diluted earnings per share $ 1.06 $ 1.04 $ 3.19 $ 3.14

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Compensation Expense Information	The following table provides information regarding our stock-based compensation: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2023 2022 2023 2022 Pre-tax stock-based compensation costs charged against income $ 2,449 $ 2,433 $ 10,283 $ 9,756 Income tax benefit recognized on compensation costs $ 241 $ 49 $ 910 $ 924 Total fair value of options and RSUs vested during the period $ — $ 63 $ 12,213 $ 10,352 Cash received from the exercise of stock options $ 1,635 $ 5,684 $ 10,818 $ 7,173 Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises $ 351 $ 731 $ 1,490 $ 3,626
Summary of Restricted Shares	A summary of the RSUs granted under the 2005 Plan and the 2020 Plan is presented below: RSUs Shares (in thousands) Weighted Nine Months Ended December 31, 2022 Unvested at March 31, 2022 440.9 $ 38.45 Granted 151.0 55.03 Incremental performance shares 42.4 — Vested (223.4) 32.09 Forfeited (1.9) 49.51 Unvested at December 31, 2022 409.0 47.17 Vested at December 31, 2022 108.5 36.54 Nine Months Ended December 31, 2023 Unvested at March 31, 2023 409.0 $ 47.17 Granted 157.1 62.06 Incremental performance shares 41.4 — Vested (205.0) 43.17 Forfeited (10.6) 52.68 Unvested at December 31, 2023 391.9 54.43 Vested at December 31, 2023 110.2 38.77
Fair Value of Options Granted	The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions presented below: Nine Months Ended December 31, 2023 2022 Expected volatility 30.2% - 31.6% 30.8% - 30.9% Expected dividends $ — $ — Expected term in years 6.0 to 7.0 6.0 to 7.0 Risk-free rate 3.6% to 4.1% 2.8% to 2.9% Weighted average grant date fair value of options granted $ 23.79 $ 20.10
Stock Option Activity	A summary of option activity under the 2005 Plan and the 2020 Plan is as follows: Options Shares (in thousands) Weighted Weighted Aggregate Nine Months Ended December 31, 2022 Outstanding at March 31, 2022 1,100.9 $ 40.62 Granted 197.6 54.48 Exercised (200.2) 35.82 Forfeited (10.3) 49.53 Expired (0.8) 44.33 Outstanding at December 31, 2022 1,087.2 43.94 6.7 $ 20,289 Vested at December 31, 2022 670.5 41.18 5.4 $ 14,360 Nine Months Ended December 31, 2023 Outstanding at March 31, 2023 1,081.0 $ 43.96 Granted 131.1 61.81 Exercised (268.9) 40.23 Forfeited (41.0) 54.15 Expired (2.8) 54.47 Outstanding at December 31, 2023 899.4 47.18 6.2 $ 12,703 Vested at December 31, 2023 606.2 43.23 5.0 $ 10,903

Business Segments (Tables)

Business Segments (Tables)	9 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Operating and Reportable Segments	The tables below summarize information about our reportable segments. Three Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 236,565 $ 46,176 $ 282,741 Cost of sales 106,090 18,713 124,803 Gross profit 130,475 27,463 157,938 Advertising and marketing 33,917 5,549 39,466 Contribution margin $ 96,558 $ 21,914 $ 118,472 Other operating expenses 31,640 Operating income $ 86,832 * Intersegment revenues of $0.5 million were eliminated from the North American OTC Healthcare segment. Nine Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 727,131 $ 121,235 $ 848,366 Cost of sales 323,632 52,103 375,735 Gross profit 403,499 69,132 472,631 Advertising and marketing 100,707 15,092 115,799 Contribution margin $ 302,792 $ 54,040 $ 356,832 Other operating expenses 96,556 Operating income $ 260,276 * Intersegment revenues of $2.5 million were eliminated from the North American OTC Healthcare segment. Three Months Ended December 31, 2022 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 236,884 $ 38,640 $ 275,524 Cost of sales 110,554 14,568 125,122 Gross profit 126,330 24,072 150,402 Advertising and marketing 24,831 5,592 30,423 Contribution margin $ 101,499 $ 18,480 $ 119,979 Other operating expenses 32,795 Operating income $ 87,184 * Intersegment revenues of $1.1 million were eliminated from the North American OTC Healthcare segment. Nine Months Ended December 31, 2022 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 731,456 $ 110,400 $ 841,856 Cost of sales 327,008 43,318 370,326 Gross profit 404,448 67,082 471,530 Advertising and marketing 99,559 14,634 114,193 Contribution margin $ 304,889 $ 52,448 $ 357,337 Other operating expenses 98,755 Operating income $ 258,582 * Intersegment revenues of $2.8 million were eliminated from the North American OTC Healthcare segment.
Revenues from Similar Product Groups	The tables below summarize information about our segment revenues from similar product groups. Three Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Analgesics $ 28,680 $ 1,586 $ 30,266 Cough & Cold 27,359 5,814 33,173 Women's Health 53,076 5,190 58,266 Gastrointestinal 38,919 22,707 61,626 Eye & Ear Care 38,503 6,569 45,072 Dermatologicals 26,603 1,165 27,768 Oral Care 20,362 3,100 23,462 Other OTC 3,063 45 3,108 Total segment revenues $ 236,565 $ 46,176 $ 282,741 Nine Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Analgesics $ 85,838 $ 3,814 $ 89,652 Cough & Cold 73,703 19,129 92,832 Women's Health 163,031 17,218 180,249 Gastrointestinal 122,303 49,678 171,981 Eye & Ear Care 117,719 17,715 135,434 Dermatologicals 94,299 3,972 98,271 Oral Care 61,400 9,591 70,991 Other OTC 8,838 118 8,956 Total segment revenues $ 727,131 $ 121,235 $ 848,366 Three Months Ended December 31, 2022 (In thousands) North American OTC International OTC Consolidated Analgesics $ 29,396 $ 648 $ 30,044 Cough & Cold 31,246 6,336 37,582 Women's Health 53,918 4,138 58,056 Gastrointestinal 38,194 18,555 56,749 Eye & Ear Care 32,653 5,229 37,882 Dermatologicals 27,223 978 28,201 Oral Care 21,371 2,738 24,109 Other OTC 2,883 18 2,901 Total segment revenues $ 236,884 $ 38,640 $ 275,524 Nine Months Ended December 31, 2022 (In thousands) North American OTC International OTC Consolidated Analgesics $ 89,943 $ 1,642 $ 91,585 Cough & Cold 76,896 19,775 96,671 Women's Health 174,481 13,750 188,231 Gastrointestinal 119,533 48,619 168,152 Eye & Ear Care 109,225 14,699 123,924 Dermatologicals 89,550 2,886 92,436 Oral Care 63,597 8,988 72,585 Other OTC 8,231 41 8,272 Total segment revenues $ 731,456 $ 110,400 $ 841,856

Inventories - Summary of Invent

Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 22,093	$ 20,634
Work in process	555	220
Finished goods	125,989	141,267
Inventories	$ 148,637	$ 162,121

Inventories - Narrative (Detail

Inventories - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2023	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 5.8	$ 5.8

Goodwill - Schedule of Changes

Goodwill - Schedule of Changes (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill, gross, beginning	$ 741,656
Accumulated impairment loss, beginning	(214,103)
Goodwill, net, beginning	527,553
Effects of foreign currency exchange rates	325
Goodwill, gross, ending	741,981
Accumulated impairment loss, ending	(214,103)
Goodwill, net, ending	527,878
North American OTC Healthcare
Goodwill [Roll Forward]
Goodwill, gross, beginning	711,452
Accumulated impairment loss, beginning	(212,516)
Goodwill, net, beginning	498,936
Effects of foreign currency exchange rates	0
Goodwill, gross, ending	711,452
Accumulated impairment loss, ending	(212,516)
Goodwill, net, ending	498,936
International OTC Healthcare
Goodwill [Roll Forward]
Goodwill, gross, beginning	30,204
Accumulated impairment loss, beginning	(1,587)
Goodwill, net, beginning	28,617
Effects of foreign currency exchange rates	325
Goodwill, gross, ending	30,529
Accumulated impairment loss, ending	(1,587)
Goodwill, net, ending	$ 28,942

Goodwill - Narrative (Details)

Goodwill - Narrative (Details) $ in Millions	12 Months Ended
	Mar. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, impairment loss	$ 48.8

Intangible Assets, net - Activi

Intangible Assets, net - Activity Affecting Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance			$ 2,580,020
Totals, effects of foreign currency exchange rate			1,557
Totals, gross, ending balance	$ 2,581,577		2,581,577
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Accumulated amortization, beginning balance			238,127
Accumulated amortization, additions	4,900	$ 5,600	14,842	$ 16,900
Accumulated amortization, effects of foreign exchange rates			79
Accumulated amortization, ending balance	253,048		253,048
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, net	158,404		158,404
Intangible Assets, Net [Abstract]
Intangible assets, net	2,328,529		2,328,529		$ 2,341,893
Finite-Lived Trademarks and Customer Relationships
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived trademarks and customer relationships, beginning balance			411,118
Finite-lived trademarks and customer relationships, effects of foreign currency exchange rate			334
Finite-lived trademarks and customer relationships, ending balance	411,452		411,452
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Accumulated amortization, beginning balance			238,127
Accumulated amortization, additions			14,842
Accumulated amortization, effects of foreign exchange rates			79
Accumulated amortization, ending balance	253,048		253,048
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, net	158,404		158,404
Indefinite-Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived trademarks, beginning balance			2,168,902
Indefinite lived trademarks, effects of foreign currency exchange rate			1,223
Indefinite-lived trademarks, ending balance	$ 2,170,125		$ 2,170,125

Intangible Assets, net - Narrat

Intangible Assets, net - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 4,900	$ 5,600	$ 14,842	$ 16,900
Impairment of intangible assets					$ 321,400
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	10 years		10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	25 years		25 years

Intangible Assets, net - Future

Intangible Assets, net - Future Amortization of Intangible Assets (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024 (remaining three months ended March 31, 2024)	$ 4,947
2025	18,115
2026	16,165
2027	14,574
2028	12,237
Thereafter	92,366
Finite-lived intangible assets, net	$ 158,404

Leases - Lease Cost (Details)

Leases - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Finance lease cost, amortization of right-of-use assets	$ 665	$ 665	$ 1,994	$ 1,994
Finance lease cost, interest on lease liabilities	20	41	74	136
Operating lease cost	1,624	1,621	4,872	4,872
Short term lease cost	34	35	101	120
Variable lease cost	14,488	14,727	47,885	43,742
Total net lease cost	$ 16,831	$ 17,089	$ 54,926	$ 50,864

Leases - Lease Maturities (Deta

Leases - Lease Maturities (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Operating Leases
2024 (remaining three months ending March 31, 2024)	$ 1,806
2025	4,834
2026	2,348
2027	1,916
2028	1,437
Thereafter	265
Total undiscounted lease payments	12,606
Less amount of lease payments representing interest	(818)
Total present value of lease payments	11,788
Finance Lease
2024 (remaining three months ending March 31, 2024)	731
2025	1,509
2026	96
2027	80
2028	0
Thereafter	0
Total undiscounted lease payments	2,416
Less amount of lease payments representing interest	(33)
Total present value of lease payments	2,383
Total
2024 (remaining three months ending March 31, 2024)	2,537
2025	6,343
2026	2,444
2027	1,996
2028	1,437
Thereafter	265
Total undiscounted lease payments	15,022
Less amount of lease payments representing interest	(851)
Total present value of lease payments	$ 14,171

Leases - Additional Information

Leases - Additional Information (Details)	Dec. 31, 2023
Weighted average remaining lease term (years)
Operating leases	2 years 11 months 12 days
Finance leases	1 year 10 days
Weighted average discount rate
Operating leases	3.80%
Finance leases	2.93%

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Payables and Accruals [Abstract]
Accrued marketing costs	$ 29,648	$ 30,471
Accrued compensation costs	9,940	14,292
Accrued broker commissions	1,888	1,767
Income taxes payable	5,953	10,645
Accrued professional fees	5,100	4,254
Accrued production costs	4,568	5,700
Other accrued liabilities	7,966	5,395
Total other accrued liabilities	$ 65,063	$ 72,524

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2023	Mar. 31, 2023
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 1,210,000
Long-term debt, net	1,210,000	$ 1,360,000
Less: unamortized debt costs	(10,660)	(14,212)
Long-term debt, net	$ 1,199,340	1,345,788
Senior Notes | 2021 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate	3.75%
Total long-term debt (including current portion)	$ 600,000	600,000
Senior Notes | 2019 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate	5.125%
Total long-term debt (including current portion)	$ 400,000	400,000
Term Loans | 2012 Term B-5 Loans
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 210,000	$ 360,000
Term Loans | 2012 Term B-5 Loans | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		2%
Debt instrument, variable rate, minimum		0.50%
Term Loans | 2012 Term B-5 Loans | Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		1%
Term Loans | 2012 Term B-5 Loans | SOFR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	2%

Long-Term Debt - Narrative (Det

Long-Term Debt - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 08, 2023	Dec. 07, 2023
Debt Instrument [Line Items]
Long-term debt outstanding	$ 1,210,000
Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Long-term debt outstanding	0
Borrowing capacity	$ 168,900	$ 200,000	$ 175,000

Long-Term Debt - Maturities of

Long-Term Debt - Maturities of Long-term Debt (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Aggregate Future Principal Payments
2024 (remaining three months ending March 31, 2024)	$ 0
2025	0
2026	0
2027	0
2028	400,000
Thereafter	810,000
Total long-term debt (including current portion)	$ 1,210,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Senior Notes | 2019 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 400,000	$ 400,000
Senior Notes | 2021 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	600,000	600,000
Term Loans | 2012 Term B-5 Loans | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	210,000	360,000
Fair Value, Measurements, Recurring | Senior Notes | 2019 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	391,000	383,500
Fair Value, Measurements, Recurring | Senior Notes | 2021 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	523,500	510,750
Fair Value, Measurements, Recurring | Term Loans | 2012 Term B-5 Loans | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 210,263	$ 359,550

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details)	9 Months Ended
	Dec. 31, 2023 USD ($) vote $ / shares shares	May 02, 2023 USD ($)	Mar. 31, 2023 $ / shares shares
Stockholders' Equity Note [Abstract]
Common stock, shares authorized (in shares) | shares	250,000,000		250,000,000
Common stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01
Preferred stock, shares authorized (in shares) | shares	5,000,000		5,000,000
Preferred stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01
Voting rights, number of votes per common share owned | vote	1
Dividends declared on common stock | $	$ 0
Stock repurchase program, authorized amount | $		$ 25,000,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Repurchased Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Total amount repurchased		$ 16	$ 30,524	$ 55,466
Share Repurchase Program
Class of Stock [Line Items]
Number of shares (in shares)	0	0	426,479	914,236
Average price per share (in USD per share)	$ 0	$ 0	$ 58.62	$ 54.69
Total amount repurchased	$ 0	$ 0	$ 25,000	$ 50,000
Restricted Shares
Class of Stock [Line Items]
Number of shares (in shares)	0	303	88,953	99,522
Average price per share (in USD per share)	$ 0	$ 50.63	$ 61.92	$ 54.92
Total amount repurchased	$ 0	$ 20	$ 5,500	$ 5,500

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Components of AOCL (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	$ 1,600,577	$ 1,535,959	$ 1,447,084	$ 1,686,863	$ 1,619,841	$ 1,577,611
Accumulated other comprehensive loss, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	(28,529)	$ (35,994)	(31,564)	$ (29,489)	$ (36,459)	$ (19,032)
Cumulative translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	(29,245)		(32,280)
Unrecognized net gain on pension plans, net of tax of $(214) and $(214), respectively
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	716		716
Unrecognized net gain on pension plan, tax	$ (214)		$ (214)

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Loss - Narrative (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2023	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Reclassification from accumulated other comprehensive loss into earnings	$ 0	$ 0

Earnings Per Share - Computatio

Earnings Per Share - Computation of Basis and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Numerator
Net income	$ 53,046	$ 51,951	$ 159,881	$ 158,246
Denominator
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	49,740	49,693	49,731	49,919
Dilutive effect of unvested restricted stock units and options issued to employees and directors (in shares)	385	493	403	473
Denominator for diluted earnings per share (in shares)	50,125	50,186	50,134	50,392
Earnings per Common Share:
Basic earnings per share (in USD per share)	$ 1.07	$ 1.05	$ 3.21	$ 3.17
Diluted earnings per share (in USD per share)	$ 1.06	$ 1.04	$ 3.19	$ 3.14

Earnings Per Share - Antidiluti

Earnings Per Share - Antidilutive Securities (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	0.3	0.2	0.3	0.4

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	Jun. 30, 2014	Dec. 31, 2023	Jun. 23, 2020	May 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to nonvested awards		$ 3.1
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition (years)		1 year 10 months 24 days
Shares available for issuance under the Plan (in shares)		1,900,000
Options exercised, aggregate intrinsic value		$ 5.4
Restricted Stock Units (RSUs) & Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to nonvested awards		$ 12.9
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition (years)		1 year 8 months 12 days
Long-term Equity Incentive Plan, 2005
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for grant (in shares)				5,000,000
Number of additional shares authorized (in shares)	1,800,000
Long-term Incentive Plan, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			2,827,210
Number of new shares for future issuance under 2020 long-term incentive plans (in shares)			2,000,000
Number of unissued shares reserved for 2020 long-term incentive plans (in shares)			827,210

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Based Compensation Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Pre-tax stock-based compensation costs charged against income	$ 2,449	$ 2,433	$ 10,283	$ 9,756
Income tax benefit recognized on compensation costs	241	49	910	924
Total fair value of options and RSUs vested during the period	0	63	12,213	10,352
Cash received from the exercise of stock options	1,635	5,684	10,818	7,173
Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises	$ 351	$ 731	$ 1,490	$ 3,626

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Shares
Outstanding, beginning of period (in shares)	409,000	440,900
Granted (in shares)	157,100	151,000
Incremental performance shares (in shares)	41,400	42,400
Vested (in shares)	(205,000)	(223,400)
Forfeited (in shares)	(10,600)	(1,900)
Outstanding, end of period (in shares)	391,900	409,000
Vested, end of period (in shares)	110,200	108,500
Weighted Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)	$ 47.17	$ 38.45
Granted, weighted-average grant-date fair value (in USD per share)	62.06	55.03
Vested, weighted-average grant-date fair value (in USD per share)	43.17	32.09
Forfeited, weighted-average grant-date fair value (in USD per share)	52.68	49.51
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)	54.43	47.17
Vested, end of period, weighted-average grant-date fair value (in USD per share)	$ 38.77	$ 36.54

Stock-Based Compensation - St_2

Stock-Based Compensation - Stock Option Valuation Assumptions (Details) - Stock Options - USD ($)	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	$ 0	$ 0
Granted, weighted-average grant-date fair value (in USD per share)	$ 23.79	$ 20.10
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	30.20%	30.80%
Expected term in years	6 years	6 years
Risk-free rate	3.60%	2.80%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	31.60%	30.90%
Expected term in years	7 years	7 years
Risk-free rate	4.10%	2.90%

Stock-Based Compensation - St_3

Stock-Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Shares
Outstanding, beginning of period (in shares)	1,081,000	1,100,900
Granted (in shares)	131,100	197,600
Exercised (in shares)	(268,900)	(200,200)
Forfeited (in shares)	(41,000)	(10,300)
Expired (in shares)	(2,800)	(800)
Outstanding, end of period (in shares)	899,400	1,087,200
Exercisable, end of period (in shares)	606,200	670,500
Weighted Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 43.96	$ 40.62
Granted, weighted-average exercise price (in USD per share)	61.81	54.48
Exercised, weighted-average exercise price (in USD per share)	40.23	35.82
Forfeited, weighted-average exercise price (in USD per share)	54.15	49.53
Expired, weighted-average exercise price (in USD per share)	54.47	44.33
Outstanding, end of period, weighted-average exercise price (in USD per share)	47.18	43.94
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 43.23	$ 41.18
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	6 years 2 months 12 days	6 years 8 months 12 days
Exercisable, end of period, weighted-average remaining contractual term	5 years	5 years 4 months 24 days
Outstanding, end of period, aggregate intrinsic value	$ 12,703	$ 20,289
Exercisable, end of period, aggregate intrinsic value	$ 10,903	$ 14,360

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Effective income tax rate	23.80%	23.70%	23.40%	23%

Concentrations of Risk (Details

Concentrations of Risk (Details) - manufacturer	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Concentration Risk [Line Items]
Number of third-party manufacturers	129	133	129	133
Sales | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	19%	19.90%	19.60%	19.80%
Sales | Customer Concentration Risk | Amazon
Concentration Risk [Line Items]
Concentration risk, percentage	10.70%		10.40%
Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Number of third-party manufacturers with long-term contracts			27	27
Top 5 brands | Sales | Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	37%	36.90%	37.80%	38.70%
Manufacturers | Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			72.10%	70.50%

Business Segments - Information

Business Segments - Information on Operating and Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information, Profit (Loss):
Total revenues	$ 282,741	$ 275,524	$ 848,366	$ 841,856
Cost of sales	124,803	125,122	375,735	370,326
Gross profit	157,938	150,402	472,631	471,530
Advertising and marketing	39,466	30,423	115,799	114,193
Contribution margin	118,472	119,979	356,832	357,337
Other operating expenses	31,640	32,795	96,556	98,755
Operating income	86,832	87,184	260,276	258,582
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	236,565	236,884	727,131	731,456
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	46,176	38,640	121,235	110,400
Operating Segments | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	236,565	236,884	727,131	731,456
Cost of sales	106,090	110,554	323,632	327,008
Gross profit	130,475	126,330	403,499	404,448
Advertising and marketing	33,917	24,831	100,707	99,559
Contribution margin	96,558	101,499	302,792	304,889
Operating Segments | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	46,176	38,640	121,235	110,400
Cost of sales	18,713	14,568	52,103	43,318
Gross profit	27,463	24,072	69,132	67,082
Advertising and marketing	5,549	5,592	15,092	14,634
Contribution margin	21,914	18,480	54,040	52,448
Intersegment Eliminations | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	$ 500	$ 1,100	$ 2,500	$ 2,800

Business Segments - Revenue (De

Business Segments - Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 282,741	$ 275,524	$ 848,366	$ 841,856
Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	30,266	30,044	89,652	91,585
Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	33,173	37,582	92,832	96,671
Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	58,266	58,056	180,249	188,231
Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	61,626	56,749	171,981	168,152
Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	45,072	37,882	135,434	123,924
Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	27,768	28,201	98,271	92,436
Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	23,462	24,109	70,991	72,585
Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,108	2,901	8,956	8,272
North American OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	236,565	236,884	727,131	731,456
North American OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	28,680	29,396	85,838	89,943
North American OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	27,359	31,246	73,703	76,896
North American OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	53,076	53,918	163,031	174,481
North American OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	38,919	38,194	122,303	119,533
North American OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	38,503	32,653	117,719	109,225
North American OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	26,603	27,223	94,299	89,550
North American OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	20,362	21,371	61,400	63,597
North American OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,063	2,883	8,838	8,231
International OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	46,176	38,640	121,235	110,400
International OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,586	648	3,814	1,642
International OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	5,814	6,336	19,129	19,775
International OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	5,190	4,138	17,218	13,750
International OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	22,707	18,555	49,678	48,619
International OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	6,569	5,229	17,715	14,699
International OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,165	978	3,972	2,886
International OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,100	2,738	9,591	8,988
International OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 45	$ 18	$ 118	$ 41